Evidence map›Paper›PMID 38935767›Full record

ArticlePloS one2024

Analysis of prognostic factors in critically ill patients with COVID-19.

Klaudia Bartoszewicz, Mateusz Bartoszewicz, Wojciech Gradkowski, Samuel Stróż, Anna Stasiak-Barmuta, Sławomir Lech Czaban

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Klaudia BartoszewiczDepartment of Clinical Immunology, Medical University of Bialystok, Bialystok, Poland.
Mateusz BartoszewiczDepartment of Anaesthesiology and Intensive Care, Medical University of Bialystok, Bialystok, Poland.ORCID 0000-0001-6455-6962
Wojciech GradkowskiDepartment of Anaesthesiology and Intensive Care, Medical University of Bialystok, Bialystok, Poland.
Samuel StróżDepartment of Clinical Immunology, Medical University of Bialystok, Bialystok, Poland.
Anna Stasiak-BarmutaDepartment of Clinical Immunology, Medical University of Bialystok, Bialystok, Poland.
Sławomir Lech CzabanDepartment of Anaesthesiology and Intensive Care, Medical University of Bialystok, Bialystok, Poland.ORCID 0000-0002-8938-0809

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Coronavirus Disease 2019 (COVID-19) has caused a global health crisis. Mortality predictors in critically ill patients remain under investigation. A retrospective cohort study included 201 patients admitted to the intensive care unit (ICU) due to COVID-19. Data on demographic characteristics, laboratory findings, and mortality were collected. Logistic regression analysis was conducted with various independent variables, including demographic characteristics, clinical factors, and treatment methods. The study aimed to identify key risk factors associated with mortality in an ICU. In an investigation of 201 patients comprising non-survivors (n = 80, 40%) and Survivors (n = 121, 60%), we identified several markers significantly associated with ICU mortality. Lower Interleukin 6 and White Blood Cells levels at both 24- and 48-hours post-ICU admission emerged as significant indicators of survival. The study employed logistic regression analysis to evaluate risk factors for in-ICU mortality. Analysis results revealed that demographic and clinical factors, including gender, age, and comorbidities, were not significant predictors of in-ICU mortality. Ventilator-associated pneumonia was significantly higher in Survivors, and the use of antibiotics showed a significant association with increased mortality risk in the multivariate model (OR: 11.2, p = 0.031). Our study underscores the significance of monitoring Il-6 and WBC levels within 48 hours of ICU admission, potentially influencing COVID-19 patient outcomes. These insights may reshape therapeutic strategies and ICU protocols for critically ill patients.

Indexed as

COVID-19Critical IllnessIntensive Care UnitsInterleukin-6AdultAgedFemaleHospital MortalityHumansLeukocyte CountLogistic ModelsMaleMiddle AgedPneumonia, Ventilator-AssociatedPrognosisRetrospective StudiesInterleukin-6

Identifiers

PMID38935767
PMCPMC11210843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.